Montag, 20. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

Rekrutierend

NCT-Nummer:
NCT06123468

Studienbeginn:
April 2024

Letztes Update:
19.04.2024

Wirkstoff:
Sacituzumab govitecan

Indikation (Clinical Trials):
Adenocarcinoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborator:
Gilead Sciences

Studienleiter

Salah Al-Batran, Prof. Dr.
Study Director
Frankfurter Institut für Klinische Krebsforschung IKF GmbH

Kontakt

Florian Lordick, Prof.Dr.
Kontakt:
Phone: 0049341972560
E-Mail: Florian.lordick@medizin.uni-leipzig.de» Kontaktdaten anzeigen

Studienlocations
(3 von 8)

Alle anzeigen

Studien-Informationen

Detailed Description:

All eligible enrolled patients will receive:Sacituzumab-govitecan 10 mg/kg i.v. at day 1 and

day 8 of each 21-day cycle (Q3W). Patients will receive the treatment for a maximum of 12

months or until disease progression, unacceptable toxicity or withdrawal of consent,

whichever occurs first.The primary objective of the trial is to evaluate the efficacy

(primary endpoint: Overall Response Rate ORR, complete response + partial response) of

sacituzumab-govitecan for metastatic esophagogastric adenocarcinoma. The secondary objectives

are to further characterize the efficacy of sacituzumab-govitecan for metastatic

esophagogastric adenocarcinoma and to evaluate safety and tolerability of

sacituzumab-govitecan for metastatic esophagogastric adenocarcinoma. Secondary endpoints

comprise the assessment of Clinical benefit rate (CBR, complete response + partial response +

stable disease), Progression-free survival (PFS), Overall survival (OS), ORR, CBR, PFS and OS

in the subgroup of TROP-2 overexpression, toxiticy. In addition, tissue and blood samples

will be analyzed to evaluate the TROP-2 expression during treatment with

sacituzumab-govitecan for metastatic esophagogastric adenocarcinoma.

56 patients will be enrolled in this trial.

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. Patient* has given written informed consent.

2. Patient is, in the investigator's judgement, willing and able to comply with the study

protocol.

3. Patient is ≥ 18 years of age at time of signing the written informed consent.

4. Patient has been diagnosed with histologically confirmed metastatic (stage IV)

esophagogastric adenocarcinoma.

5. Patient has received at least one prior therapy containing platinum compound and a

fluoropyrimidine, potentially combined with immunotherapy, in the metastatic setting.

Neoadjuvant/adjuvant platinum-fluoropyrimidine treatment is counted as first-line

therapy if disease progression occurred within 6 months after completion of treatment.

NOTE: patients with advanced MSI-h/dMMR tumors who have not previously been treated

with pembrolizumab, nivolumab or any other PD-1/PD-L1 inhibitor are not permitted for

inclusion.

6. Patient has an ECOG performance status ≤ 1.

7. Patient must have an estimated life expectancy of at least 12 weeks.

8. Patient has at least one measurable lesion on radiographic imaging as defined by

RECIST v1.1.

9. Patient has adequate hematological, hepatic and renal function as indicated by the

following parameters:

1. Leukocytes ≥ 2,500/μL, platelets ≥ 100,000/μL without transfusion, absolute

neutrophil count (ANC) ≥ 1,500/μL without granulocyte colony-stimulating factor

support, hemoglobin ≥ 90 g/L (9 g/dL) - Patients may be transfused to meet this

criterion.

2. Bilirubin ≤ 1.5 x upper limit of normal (ULN), aspartate transaminase and alanine

transaminase ≤ 2.5 x ULN (≤ 5 x ULN in case of liver metastases), alkaline

phosphatase ≤ 2.5 x ULN (≤ 5 x ULN in case of liver metastases)

3. Serum creatinine ≤ 1.5 x ULN, or glomerular filtration rate > 45 mL/min

(calculated per institutional standard)

4. Serum albumin ≥ 25 g/L (2.5 g/dL)

5. For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 x ULN;

for patients receiving therapeutic anticoagulation: stable anticoagulant regimen

10. Patient must be willing to provide liquid biopsy samples for the translational

research program.

11. Female patients of childbearing potential and male patients with female partners of

childbearing potential must agree to remain abstinent (refrain from heterosexual

intercourse) or use contraceptive methods that result in a failure rate of <1% per

year during the treatment period and for at least 6 months after the last study

treatment. Male patients must refrain from donating sperm during this same period.

Male patients with a pregnant partner must agree to

Exclusion Criteria:

1. Patient has known hypersensitivity to any component of the Sacituzumab-govitecan

formulation as well as a known history of severe allergic, anaphylactic or other

hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.

2. Patient has received previously topoisomerase 1 inhibitors such as irinotecan, or

nal-irinotecan

3. Patient has an active second malignancy. Note: patients with a history of malignancy

that have been completely treated, with no evidence of active cancer for 3 years prior

to enrollment, or patients with surgically cured tumors with low risk of recurrence

(e.g., non-melanoma skin cancer, histologically confirmed complete excision of

carcinoma in situ, or similar) are allowed to enroll

4. Patients with known, untreated and active (not stable within the last 4 weeks or

symptomatic) brain metastases and patients with leptomeningeal disease.

5. Patient meets any of the following criteria for cardiac disease:

1. Myocardial infarction or unstable angina pectoris within 6 months prior to

initiation of study treatment

2. History of serious ventricular arrhythmia (i.e., ventricular tachycardia or

ventricular fibrillation), high-grade atrioventricular bock, or other cardiac

arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation

that is well controlled with antiarrhythmic medication); history of QT interval

prolongation

3. New York Heart Associated (NYHA) class III or greater congestive heart failure or

left ventricular ejection fraction (LVEF) of < 40% if echocardiography has been

performed

6. Patient has an active chronic inflammatory bowel disease (ulcerative colitis, Crohn's

disease) or gastrointestinal perforation within 6 months prior to initiation of study

treatment

7. Patient has an active serious infection requiring antibiotic treatment

8. Patient has known history of human immune deficiency virus (HIV, or positive HIV

antibody, if done at screening) with detectable viral load OR taking medications that

may interfere with SN-38 metabolism

9. Patient has active hepatitis B or C virus (HBV/HCV). In patients with a history of HBV

or HCV, patients with detectable viral loads will be excluded

10. Patient participated in another interventional clinical study ≤ 14 days prior to

initiation of study treatment or at the same time as this study.

11. Patient has taken an investigational drug within 14 days or 5 half-lives (whichever is

longer) prior to initiation of study treatment.

12. Patient received anticancer biologic agent within 28 days or targeted small molecule,

radiation or chemotherapy within 14 days prior to initiation of the study treatment.

13. Patient has not recovered from AEs due to previously administered drug (i.e., ≥ grade

2 is concerned as not recovered)

1. Patients with any grade of alopecia are an exception to this criterion and will

qualify for the study

2. If patients received major surgery, they must have recovered adequately from the

toxicity and/or complications from the intervention prior to starting study

treatment

14. Patient has evidence of any other disease, neurologic or metabolic dysfunction,

physical examination finding or laboratory finding giving reasonable suspicion of a

disease or condition that contraindicates the use of any of the study medications,

puts the patient at higher risk for treatment-related complications or may affect the

interpretation of study results.

15. Female patients, who are pregnant or breast feeding or planning to become pregnant

within and 6 months after the end of treatment. Female patients of childbearing

potential must have a negative serum pregnancy test result within 7 days prior to

initiation of study treatment.

Studien-Rationale

Primary outcome:

1. Overall response rate (Time Frame - up to 12 months):
Objective response rate will be assessed according to RECIST v1.1. criteria and is defined as proportion of patients showing complete or partial response (CR+PR).



Secondary outcome:

1. Clinical benefit rate (Time Frame - up to 36 months):
Clinical benefit rate will be assessed according to RECIST v1.1. criteria and is defined as proportion of patients showing complete response, partial response or stable disease (CR+PR+SD).

2. Progression-free survival (PFS) (Time Frame - up to 36 months):
Progression-free survival is defined as time from enrollment to the date of progression according to RECIST v1.1 or death due to any cause. Patients who have not experienced an event at the time of analysis will be censored at the most recent date of disease assessment.

3. Overall survival (OS) (Time Frame - up to 36 months):
Overall survival is defined as the time from enrollment to the date of death from any cause. Patients who have not experienced an event at the time of analysis will be censored at the date when the patient was last known to be alive.

4. Safety and toxicity (Time Frame - up to 13 months (max. 12 months treatment plus 30 days after last treatment)):
Safety and tolerability assessments will include physical examinations, clinical laboratory profile and continuous assessments of adverse events (AEs). AEs will be monitored throughout the trial and graded in severity according to the guidelines outlined in the NCI CTCAE v5.0.

Geprüfte Regime

  • Sacituzumab govitecan (Trodelvy):
    10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W) for max 17 cycles (max. 12 months treatment)

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.